Edition:
United States

Aradigm Corp (ARDM.OQ)

ARDM.OQ on NASDAQ Stock Exchange Capital Market

4.68USD
11 Dec 2017
Change (% chg)

$0.34 (+7.83%)
Prev Close
$4.34
Open
$4.35
Day's High
$4.74
Day's Low
$4.24
Volume
23,808
Avg. Vol
62,348
52-wk High
$5.65
52-wk Low
$0.80

Chart for

About

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery... (more)

Overall

Beta: 8.86
Market Cap(Mil.): $70.89
Shares Outstanding(Mil.): 15.15
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Boxer Capital Reports 5.9 Pct Passive Stake In Aradigm Corp As Of Nov 30

* BOXER CAPITAL LLC REPORTS 5.9 PERCENT PASSIVE STAKE IN ARADIGM CORP AS OF NOVEMBER 30 - SEC FILING Source text: (http://bit.ly/2BDnINX) Further company coverage:

Dec 11 2017

BRIEF-Aradigm Announces FDA Advisory Committee Meeting For Linhaliq

* ARADIGM ANNOUNCES FDA ADVISORY COMMITTEE MEETING FOR LINHALIQ

Dec 01 2017

BRIEF-Aradigm Corp files for common stock offering of up to $20 mln

* Aradigm Corp files for common stock offering of up to $20 million - SEC filing‍​ Source text: (http://bit.ly/2lOJdUD) Further company coverage:

Nov 03 2017

BRIEF-Aradigm Q3 loss per share $0.26

* Aradigm corp - qtrly ‍rev $2.7 million versus $50,000​ Source text for Eikon: Further company coverage:

Nov 02 2017

BRIEF-Aradigm Corp presents analysis of results for phase 3 orbit-3, orbit-4 clinical trials

* Aradigm Corp presents analysis of results for phase 3 orbit-3 and orbit-4 clinical trials - sec filing

Jul 07 2017

BRIEF-Aradigm says Laurence Lytton reports 5.1 pct passive stake in co as of May 31, 2017 - sec filing

* Laurence W.Lytton reports a 5.1 percent passive stake in aradigm corp as of may 31, 2017 - sec filing Source text for Eikon: Further company coverage:

Jun 12 2017

Earnings vs. Estimates